Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INS37217 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| INS37217 Nasal Spray | DRUG | - |
Inclusion Criteria: * Have a documented history of allergy to perennial allergens and demonstrated sensitivity by the results of prick or intradermal skin testing. * Have a self-reported history of at least mild, intermittent rhinorrhea and nasal blockage/stuffiness due to allergies. * Have not sta...
INS37217 is an investigational small molecule being developed for the treatment of Perennial Allergic Rhinitis, a chronic allergic condition affecting the nasal passages. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
INS37217 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 2 clinical development for Perennial Allergic Rhinitis.
INS37217 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. One Phase 2 clinical trial for the drug has been completed.
INS37217 has one completed Phase 2 clinical trial, identified as NCT00210015, titled "A Study in Subjects With Perennial Allergic Rhinitis." This trial enrolled 630 participants and was completed, with no active trials currently ongoing.
INS37217 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Perennial Allergic Rhinitis. The drug has completed one Phase 2 trial, but it remains in clinical development and has not received marketing approval.